Clinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals

Similar documents
Simplifying HIV Treatment Now and in the Future

Apurba Chakraborty MBBS, MPH Dima M. Qato PharmD, MPH, PhD Professor Mark S. Dworkin MD, MPHTM The University of Illinois at Chicago

HIV TREATMENT ADHERENCE AND SUPPORT. Leonard Anang Sowah, MBChB, MPH, FACP Asst. Professor of Medicine University of Maryland Medical School

PERSPECTIVE THERXPIPELINE

Community Health Workers (CHWs) in HIV Services: Insights from Virginia. November 16, 2017

ADHERENCE AND PSYCHOSOCIAL SUPPORT FOR CHILDREN AND ADOLESCENTS

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini

Gender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project,

Memo. Implications of Proposed Rule on Medicare Part D Protected Class

Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017

Constructing antiretroviral regimens to overcome imperfect adherence

Progress against the HIV Epidemic: is the end in sight?

targets for HIV-positive children

Presented at International Violence, Abuse and Trauma Conference Dr. Priscilla Dass-Brailsford Georgetown University Washington DC

Brantley M. Underwood Pharm.D., MBA PGY1 Community Pharmacy Resident Southwestern Oklahoma State University/Walgreen Co

Comprehensive HIV/AIDS Resources and Linkages for Inmates (CHARLI) and Care Coordination (CC) Collaborative. Care Coordination

ASSESSING ADHERENCE TO COMBINATION ART IN AN URBAN PRIVATE HOSPITAL DR. EVELYN MBUGUA AGA KHAN UNIVERSITY HOSPITAL

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:

Needs Assessment of People Living with HIV in the Boston EMA. Needs Resources and Allocations Committee March 10 th, 2016

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.

CCTs and HIV care: Preliminary results and priority areas for intervention

Use of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist

Evolving HIV Treatment Paradigms What we need to know

HIV: The Great Debate On Clinical Approach Vs. Cost Considerations

HIV/AIDS Bureau Update

Continuing Education for Pharmacy Technicians

PRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March

Integrating HIV Care into Primary Care Settings: Two paths to improving the HIV continuum

Second and third line paediatric ART strategies

Ensure access to and compliance with treatment for low-income uninsured Virginia residents living with HIV/AIDS

GOAL1 GOAL 2 GOAL 3 GOAL 4

UPDATE ON THE CLINICAL MANAGEMENT OF HIV IN BARBADOS

GEORGIA STATEWIDE MSM STRATEGIC PLAN

Selecting an Initial Antiretroviral Therapy (ART) Regimen

PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV

Miami-Dade County Getting to Zero HIV/AIDS Task Force Implementation Report

Housing / Lack of Housing and HIV Prevention and Care

DNA Genotyping in HIV Infection

Miami-Dade County Getting to Zero HIV/AIDS Report

Clinical and Public Health Policy Implications of Findings that:

New England healthcare providers perceptions, knowledge and practices regarding the use of antiretrovirals for prevention

Structured Guidance for Postpartum Retention in HIV Care

Culturally Relevant Linkages to Care

Understanding contraceptive choices among a cohort of HIV-positive women

Tomasz Z. Jodlowski, Pharm.D., BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases VA North Texas HCS

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily

State HIV Allocations in Baltimore

Advancing the National HIV/AIDS Strategy: Housing and the HCCI. Housing Summit Los Angeles, CA

Antiretroviral therapy (ART) is the cornerstone of treatment

Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016

Dr Marta Boffito. Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000:

Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know

When to start: guidelines comparison

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters

A Self-Reported Adherence Measure to Screen for Elevated HIV Viral Load in Pregnant and Postpartum Women on Antiretroviral Therapy

Retention and adherence: evidence-based strategies. Dr Catherine Orrell Desmond Tutu HIV Centre

Measure #340 (NQF 2079): HIV Medical Visit Frequency - National Quality Strategy Domain: Efficiency And Cost Reduction

Fulton County Board of Health Strategy to End the HIV Epidemic in Fulton County

Differentiated Care for Antiretroviral Therapy for Key Populations: Case Examples from the LINKAGES Project

Disparities in HIV Care. Slides prepared by Kirk Fergus, Intern National Quality Center

Patient Involvement in Pharmacovigilance: The Development of an HIV Peer Educator Program

HIV PREP THE NEWEST TOOL IN THE BOX

Original Research PHARMACY PRACTICE

State of Alabama AIDS Drug Assistance Program (ADAP) Quarterly Report

Didactic Series. Update on DHHS Guidelines for HIV Treatment: Adherence to the Care Continuum

Adherence And Nutrition. Emanueli Msuya Moshi Kilimanjaro Tanzania And Shonte Daniels Azusa California

2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall

Reportback from the 2013 ICAAC in Denver, CO

therapy among HIV positive youth, Uganda

Patient s perceptions of switching from Atripla to Truvada and generic efavirenz

Durable Viral Suppression among HIV Care Coordination Participants and Nonparticipants

See Important Reminder at the end of this policy for important regulatory and legal information.

COMBINING DATA SOURCES TO EVALUATE HIV HOUSING PROGRAMS: EXAMPLES

HIV and Paediatrics in Central Europe

Natural history of HIV Infection

PHARMACIST INVOLVEMENT IN HIV CARE. Alftan D. Dyson, Pharm.D., BCACP, AAHIVP Clinical Pharmacist, Medical Advocacy and Outreach

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

Adherence in adolescents- what works? Audrey Pettifor PhD University of North Carolina at Chapel Hill

Adolescents and HIV in 2018: No Youth Left Behind

Elements of the Care Continuum

Scottish Medicines Consortium

CARE FOR HIV PATIENTS IN RURAL SOUTH AFRICA

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

Sculpting a Better Regimen: The ART of HIV Medications

Principles of Antiretroviral Therapy

The Relationship Between Alcohol Use and HIV in MSM

STATEMENT OF DISCLOSURE

Co-occurring Psychosocial Health Disparities and ARV Medication Adherence among Indigent HIV-positive Patients who Use Drugs

Strategic use of antiretroviral drugs to prevent HIV transmission

Date of study period: April 12 May 7, 2010 and August September, 2010

Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations

HIV Management Update 2015

Low-Level Viremia in HIV

Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART

Assessing Clinic-Level Factors that Impact Viral Load Suppression

Transcription:

Clinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals Abstract #18 IRB Approved Jeannie Ong, Pharm.D., AAHIVP PGY2 HIV Pharmacotherapy Resident University of Oklahoma Oklahoma City, OK Infectious Diseases Institute (IDI) Federally funded by the Ryan White HIV/AIDS Program Multidisciplinary team Pharmacists provide Medication therapy management Medication adherence assessment Monthly pill box fill service Initial counseling with newly diagnosed HIV patients or patients returning into medical care Provides care to over 1,800 patients annually 4 Disclosure Jeannie Ong Potential conflicts of interest: none Sponsorship: none Proprietary information or results of ongoing research may be subject to different interpretations Speaker s presentation is educational in nature and indicates agreement to abide by the non-commercialism guidelines provided OU Pharmacist Care Center University of Oklahoma College of Pharmacy operated clinic located on the OUHSC campus HIV/AIDS Drug Assistance Program (ADAP) Retail and mail-order service for all Oklahoma residents receiving ADAP services 2 5 Learning Objectives 1. Recognize the importance of medication adherence and its clinical impact on HIV-infected patients 2. Identify various factors why patients might be ineligible for single tablet regimens for the treatment of HIV Pharmacist Pre-Test Assessment 3 6 1

Introduction ART Key Points HIV & AIDS >1.2 million Americans 1 in 8 are unaware Goals of HIV antiretroviral therapy (ART) Achieve viral suppression Restore and preserve immunologic function Reduce morbidity and prolong duration/quality of survival Reduce viral mutations Prevent HIV transmission Medication adherence Same time everyday All or nothing Do not split regimen take together Pill boxes Alarm clocks Key chains Calendars Mobile apps Motivational interviewing Education CDC. HIV/AIDS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 7 10 Single Tablet Regimens (STRs) Barriers to Medication Adherence Pill burden Side effects Cost Perceived importance Stigma Denial Mental illness Substance abuse Psychosocial factors Homelessness Lack of social support Multi-factoral Positively Aware. http://positivelyaware.com 8 11 Multi-Tablet Regimens (MTRs) Presence of viral mutations leading to medication resistance Formulary issues (hospital or department of corrections) Patient specific characteristics (i.e. renal function) Drug intolerance Drug-drug interactions Medication Adherence HIV medication adherence goal 95% 99 patients utilizing computerized caps Based on one type of therapy that was MTR Based on now obsolete therapy 9 Paterson DL, et. al. Ann Intern Med. 2000;133:21-30. 12 2

First FDA-Approved STR 2006 Atripla Current Practice Atripla Currently alternative therapy CNS effects: strange vivid dreams, dizziness, drowsiness Current data: Lacking on the comparative effectiveness of newer formulated STRs compared with MTRs 13 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 16 Since the Approval of Atripla Study Questions STRs have been associated with: Reduced pill burden Improved medication adherence Higher patient satisfaction Virologic suppression Fewer hospitalization Reducing healthcare costs 1. What adherence threshold is associated with viral suppression? 2. Do STRs still improve medication adherence and viral suppression compared to MTRs? Paterson DL, et. al. Ann Intern Med. 2000;133:21-30. Cohen CJ, et al. BMJ Open 2013;3:e003028. Bangsberg DR, et al. AIDS. 2010 Nov 27;24(18):2835-40. 14 17 FDA-Approved STRs Other Current Studies 2006 Atripla 2012 Stribild 2015 Genvoya Dr. Marcus Tad Autry: Adherence rates among regimens in treatment-naïve patients only 2011 Complera 2014 Triumeq 2016 Odefsey Dr. Krista Williams: Adherence rates of integrase inhibitor-based regimens compared to other ARV classes 15 18 3

Study Aims Objective: examine the clinical outcomes of fixed-dose, single tablet regimens compared to multi-tablet regimens in HIV-infected individuals Clinical hypothesis: whether HIV-infected individuals taking STR antiretroviral therapy experience better clinical outcomes compared to individuals taking MTR Medication Possession Ratio (MPR) Utilizes pharmacy claims data Perfect adherence will be reported as 100% Possible for MPR to exceed 100% 19 22 Methods Single-center, retrospective, observational study OU Infectious Disease Institute clinic between 2011 and 2016 Disease parameters - baseline CD4 cell count, plasma HIV RNA, date of HIV diagnosis, co-morbidities Demographic - age, race, sex, HIV risk category, HIV treatment naïve or experienced, ART Methods Inclusion Criteria HIV-infected 6 months ART 4 viral loads (AUC) Exclusion Criteria Outside pharmacy Incarceration < 6 months ART < 4 viral loads 20 23 Statistical Analysis Descriptive statistics for patient demographics Medication possession ratio will be calculated to analyze refill claims data to assess patient adherence to antiretroviral therapy Viral load AUC estimates viral control over time Multivariate regression analysis examines the relationship between MPR and viral load AUC Marginal effects analysis examines the probability of achieving viral suppression with MPR levels Endpoints Primary MPR Virologic suppression Secondary Effects on MPR Gender Race/ethnicity Age Exposure risk factor(s) 21 24 4

Results & Conclusion Pharmacist Post-Test Assessment Phase I: Enrollment Phase II: Data Collection Phase III: Data Analysis 25 28 Hypothesis It is our prediction that patients receiving STR will demonstrate improved clinical outcomes such as superior medication adherence and will achieve higher rates of virologic suppression Clinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals 26 Abstract #18 IRB Approved Jeannie Ong, Pharm.D., AAHIVP PGY2 HIV Pharmacotherapy Resident University of Oklahoma Oklahoma City, OK Pharmacist Post-Test Assessment 27 5